Venture groups within major life science companies are key pieces of the complicated funding puzzle. Don’t just take our word for it. We asked traditional VCs about their corporate counterparts; 19% said they are crucial right now to the funding landscape, and 61% said they were important. (See Exhibit 1.)
Corporate Venture Eyes The Early Stage
In our second annual Life Science Venture Survey, VCs paid their respects to the importance of corporate investors right now. For their part, corporate investors, many from long-established programs, said they are bullish about making more bets in early-stage companies.